These results suggest that Rab25 can negatively regulate the antitumour effect of EGFR‐TKI and is a biomarker for predicting the curative effect of EGFR‐TKI therapy in NSCLC. The gene discussed is RAB25; the disease is non-small cell lung carcinoma.